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RESPONSE: ANTICIPATING NEW MEDICATIONS 
Michael P. Bogenschutz, M.D.; Lawrence J. DeMarzo; and John Roll, Ph.D. 
Lawrence DeMarzo: My agency, House of 
the Crossroads, like other drug-free com­
munity-based agencies, has historically cho­
sen not to use medications in its treatment 
regimens. That is changing now, through 
our involvement in NIDA’s Clinical Trials 
Network and our acquaintance with litera­
ture like Dr. Kampman’s article (Kampman, 
2008). 
Much has changed since we started Cross­
roads. We know a lot more about addiction 
and treatment than we did 40 years ago. 
Although the agency is not using any med­
ications yet, we are considering implementing 
a methadone-to-abstinence model for heroin 
abusers. Methadone appeals to us, because 
we have seen that it works, and because it 
seems to be a service line that produces sta­
ble utilization and retention, which a fee-
for-service structure needs to generate rev­
enue to cover the cost of care. I was impressed 
and encouraged by Dr. Kampman’s positive 
outlook on the potential for medications to 
treat stimulant abuse. The drugs in this class, 
particularly crack cocaine and metham­
phetamine, have had the most devastating 
effects on our community and present the 
greatest challenge to us in terms of provid­
ing effective treatment. 
Michael Bogenschutz: At our large, outpa­
tient substance abuse program at the Uni­
versity of New Mexico, we generally try to 
treat drug abusers pharmacologically to help 
them through detoxification. We used aman­
tadine for a number of years and have also 
used a number of other medications—includ­
ing baclofen, disulfiram, and propranolol— 
based on what has seemed most promis­
ing at the time. With each of these medications, 
some patients will say that it made a big dif­
ference. I believe they help, but I wonder 
how much. The empirical findings for all 
of them are still equivocal—some promis­
ing results on the one hand, but without 
substantiation in large clinical trials. On the 
other hand, I am sure that the structure and 
support we supply along with medications 
contribute significantly to our patients’ recov­
eries. 
John Roll: Do you think those medications 
you use affect addiction directly or do 
they affect co-occurring psychiatric condi­
tions that may be enabling or facilitating 
the drug use? 
Bogenschutz: I think they affect addition 
directly. These patients are in our primary 
addiction treatment program, and they may 
or may not have co-occurring disorders. We 
target early withdrawal symptoms, like crav­
ing, and hope to normalize the function 
of a person’s brain. Disulfiram or gamma­
aminobutyric acid (GABA)-ergic medica­
tions can also affect the reinforcement value 
or effects of cocaine or methamphetamine. 
Roll: One point that I think bears high­
lighting is that medications compensate for 
some of the reinforcing effects of drugs, but 
only some. At one level, drugs reinforce 
abuse because of their pharmacology, and 
it makes perfect sense to target those aspects 
of reinforcement with pharmaceutical inter­
ventions. However, drugs also accrue rein­
forcing efficacy by other means, like the asso­
ciations of a drug-using peer group. I’ve 
heard anecdotal evidence that some women 
initiate use of methamphetamine to take 
advantage of its anorectic properties and 
control weight. Sex workers have told me 
that they could never do their job without 
drugs, so they have an economic incentive 
to continue using them. Medications don’t 
directly modify these sorts of reinforcement 
and therefore may not constitute treatment 
all by themselves. 
Bogenschutz: A good example of that point 
is the experience with naltrexone. When 
naltrexone was first released, many thought 
it would be 100 percent effective for opiate 
dependence, because it functions like an 
antidote for heroin. However, in the real 
world, naltrexone has had only a small impact 
on opioid dependence treatment. Most 
patients simply won’t take it; it causes dys­
phoria in opiate abusers, and it doesn’t decrease 
craving. Patients who do take it can simply 
stop if they want to resume heroin use. 
We would likely face similar problems with 
some of the medications Dr. Kampman dis­
cusses, particularly the cocaine vaccine. 
DeMarzo: I have heard Nora Volkow, NIDA’s 
director, make the case that developing effec­
tive medications to treat stimulant addic­
tion is an avenue to reducing the stigma of 
addiction and legitimizing addiction treat­
ment services. That makes sense to me, and 
it’s one of the reasons I find this research 
exciting. 
Grounds for implementation 
Bogenschutz: At this point, we don’t have 
a good estimate of how effective any of the 
medications being developed to treat stim­
ulant abuse are going to be. However, any 
efficacy that’s even just a little better than 
marginal is good enough to warrant imple­
menting a new medical intervention for this 
disorder. Consider Food and Drug Admin­
istration (FDA) standards as to what con­
stitutes a clinically significant benefit in the 
addiction field. There are FDA-approved 
medications for alcohol dependence, like 
naltrexone, with effect sizes of 0.2 or 0.3. 
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but it’s not atypical for medications that treat 
chronic illnesses. If many people are treated, 
the total benefit still could be quite large. 
All of the medications currently in the drug 
treatment armamentarium have relatively 
small effect sizes. The reason goes back to 
John’s comment: The pharmacological effects 
of drugs are only part of what is going on in 
addiction. Social learning, conditioning, 
and biopsychosocial factors all contribute, 
too. 
Roll: Those factors vary from person to per­
son. Before applying any approach to an 
individual patient, treatment providers need 
to do a functional analysis to see what may 
or may not work. I am not an M.D. or a 
pharmacist, but I am not aware of any med­
icine that is 100 percent effective for any 
condition. I don’t know that there will ever 
be one medication that helps everybody stop 
using drugs. 
Bogenschutz: Safety is another primary con­
cern in deciding whether to implement a 
medication intervention in a program or 
use it with a particular patient. Especially 
when using a medication off-label, that is, 
for a purpose other than the FDA-approved 
ones, the burden is on prescribers to show 
they have adequately considered the poten­
tial safety issues and have done everything 
to minimize the risks. Some of the medica­
tions Dr. Kampman discusses don’t require 
anything more than monitoring liver enzymes, 
reviewing patient history, and/or perform­
ing a physical exam to rule out cardiac dis­
ease or similar conditions. Others can pose 
significant risk. Disulfiram is perhaps the 
most promising medication mentioned in 
the article; however, it’s also probably the 
most dangerous, because the alcohol–disul­
firam interaction can be fatal, and because 
very rarely, there have been cases of patients 
developing liver failure so severe that they 
needed liver transplants. Gamma-vinyl 
GABA raises concerns about visual field 
defects. Modafinil and the anticonvulsants 
are probably pretty safe, but even they have 
sedative effects, neurological side effects, 
and potential hepatotoxicity and other organ 
effects. 
Roll: I’d add that you need to have a dis­
cussion with the patient to inform him or 
her that you’re recommending an off-label 
use of the medication and to enumerate 
potential risks. Otherwise, most patients 
will assume that your prescription is an evi­
dence-based practice, though the evidence 
is not necessarily there. 
Bogenschutz: Absolutely. In sum, from my 
perspective, clinical judgment has to be the 
primary basis for implementing or not imple­
menting use of these medications at this 
time. The evidence isn’t strong enough for 
a program to make a guideline that patients 
should receive any of them. If a program 
does decide to use one, however, it will need 
to create guidelines for using it safely. With 
disulfiram, for example, the guideline would 
require clinicians to make sure that people 
are clearly informed that the medication is 
being used off-label, that screening for adverse 
effects is appropriate, and that people get 
the information they need regarding the 
risks of using alcohol or cocaine while on 
the medication. 
DeMarzo: Cost is a big issue for us. If an 
intervention is too expensive, we simply 
won’t use it. If we, as a community-based 
agency with limited resources and experi­
ence with medical interventions, decide to 
implement a medical intervention, we have 
to consider infrastructure, training, licens­
ing regulations, and staffing issues. One of 
the greatest challenges with the transfer of 
research to practice is that researchers have 
limited resources that often do not afford 
the opportunity to build front-end, cost-
benefit analysis into the studies. 
Roll: As a researcher, I think there is so much 
that is exciting to be learned about phar­
maceutical approaches to stimulant abuse 
that I would hate to see us become overly 
concerned with cost at this stage. Once we 
get a better feel for which approaches really 
work, how, and for whom, cost will become 
a much more salient issue. 
Bogenschutz: Although cost-benefit is 
important on a systems and program level, 
cost generally drops out of the equation at 
the clinical level. The formulary or the insur­
ance company tells you what the patient can 
and can’t have. The clinician’s primary 
role with regard to these medications is to 
weigh the benefits and potential adverse 
effects. The overall clinical challenge is to 
get the most out of the mix of marginally or 
modestly effective treatments that we have 
available for stimulant abuse. Treatment 
providers will have to figure out optimal 
dosage and duration for pharmacological 
treatment, and what kinds of psychosocial 
components should be used with the par­
ticular medication or vaccine. 
The decision to use a medication or par­
ticular behavioral intervention will proba­
bly also depend on individual patient char­
acteristics, such as addiction severity, gender, 
other substances abused, psychiatric comor­
bidity, and so on. Sometimes these subgroups 
can be identified in the analyses of larger tri­
als, which may prompt subsequent trials of 
those subgroups, as was done with propra­
nolol. There’s an interesting secondary analy­
sis of the COMBINE study data for nal­
trexone showing that efficacy in that trial 
was limited to people who had a particu­
lar mu opioid receptor polymorphism (Anton 
et al., 2008). Such information may allow 
us to match treatment plans to particular 
subgroups or individuals and thus magnify 
the effects of what are now marginally effec­
tive treatments. 
Roll: I think we are just starting to figure 
out how to incorporate pharmaceuticals into 
treatment for stimulant abuse, and Dr. Kamp­
man has made a good start. He suggests a 
strategy of matching medications to the 
phase of treatment, such as initiation and 
maintenance, and I think one might do the 38 • ADDICTION SCIENCE AND CLINICAL PRACTICE—JUNE 2008 
same for behavioral psychosocial approaches, 
though it’s complicated to match a psy­
chosocial or behavioral intervention to a 
particular medication. Some research has 
shown a synergy between voucher-based 
reinforcement therapy and pharmaceutical 
treatment, but that’s just one of many pos­
sible combinations. 
Bogenschutz: As behavioral interventions 
go, the findings are most robust for con­
tingency management. However, that 
approach is used infrequently, because insur­
ance companies and the public sector are 
reluctant to fund it, and many of the treat­
ment agencies may be reluctant to imple­
ment it. 
Roll: If the cocaine vaccine should turn out 
to be effective, it will need to be delivered in 
the context of a thoughtful psychosocial 
behavioral platform as well. Even more than 
the medications, the vaccine will raise bioeth­
ical concerns about who should receive it, 
whether anyone should be compelled to 
receive it, and if so, under what circumstances. 
REFERENCES 
Anton, R.F., et al., 2008. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Phar­
macotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 65(2):135-144. 
Kampman, K.M., 2008. The search for medications to treat stimulant dependence. Addiction Science & Clinical Practice 4(2):28-35. 